A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 7-valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 27 sites in Spain. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-05.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in Spain.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent pneumococcal conjugate vaccine
Biological: 7-valent pneumococcal conjugate vaccine
1 dose at 2,4,6 and 15 months of age
1 dose at 2,4,6 and 15 months of age
Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series
Percentage of participants achieving a meningococcal C SBA serum antibody titer greater than or equal to (≥) 1:8 along with the corresponding 95% confidence interval (CI) are presented.
Time frame: One month after infant series dose (at 5 months of age)
Geometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose
Time frame: One month after infant series dose 2 (at 5 months of age) and one month after toddler dose (at 16 months of age)
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose
Predefined antibody levels for Diphtheria (0.01 or 0.1 International units \[IU\]/mL) and Tetanus (0.01 or 0.1 \[IU\]/mL).
Time frame: One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and After the Toddler Dose
Time frame: One month after infant series dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Percentage of Participants Achieving Antibody Level ≥ 0.35μg/mL in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Geometric Mean Antibody Concentration (GMC) in 13vPnC Group After the Second and the Third Dose of a 3-Dose Infant Series and After the Toddler Dose
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMCs (13vPnC) were calculated for each pneumococcal serotype and timepoint, and 2-sided, 95% CI were constructed.
Time frame: One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥ 1:8 along with the corresponding 95% confidence interval (CI) are presented.
Time frame: One month after toddler dose (at 16 months of age)
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig)(present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (Sev) (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events
Systemic events (fever \[Fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased (Decr) appetite, irritability, increased (Incr) sleep, decreased sleep, hives, use of medication (Meds) to treat symptoms (Sx), and use of medication to prevent symptoms were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Participants were recruited in Spain from 4 July 2007 to 23 July 2007.
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 223 | 226 |
| Vaccinated dose 1 | 218 | 226 |
| Vaccinated dose 2 | 217 | 222 |
| Vaccinated dose 3 | 214 | 221 |
| Completed | 213 | 220 |
| Not completed | 10 | 6 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Randomization error | 5 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 213 | 220 |
| Completed | 209 | 220 |
| Not completed | 4 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 209 | 220 |
| Completed | 208 | 220 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
Percentage of participants achieving a meningococcal C SBA serum antibody titer greater than or equal to (≥) 1:8 along with the corresponding 95% confidence interval (CI) are presented.
| percentage of participants | 13vPnC After Infant Series Dose 2 | 7vPnC After Infant Series Dose 2 |
|---|---|---|
| Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series | 98.5 (95.8 to 99.7) | 99.1 (96.7 to 99.9) |
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig)(present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (Sev) (\>7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Tenderness-Any (n=199,205,182,180,170,175,164,172) | 21.1 | 18.5 | 21.4 | 16.1 | 10.6 | 14.3 | 28.7 | 26.7 |
| Tenderness-Sig (n=199,200,177,177,167,169,154,160) | 3.0 | 4.0 | 1.1 | 4.0 | 1.2 | 1.2 | 2.6 | 3.8 |
| Swelling-Any (n=196,200,182,177,171,170,169,168) | 13.3 | 14.5 | 22.0 | 14.7 | 23.4 | 20.0 | 26.6 | 18.5 |
| Swelling-Mild (n=196,200,182,177,171,170,166,168) | 12.2 | 13.0 | 20.3 | 13.0 | 20.5 | 17.1 | 22.9 | 16.0 |
| Swelling-Mod (n=196,196,177,175,166,168,156,163) | 2.6 | 2.0 | 2.3 | 2.3 | 6.6 | 6.0 | 9.0 | 5.5 |
| Swelling-Sev (n=196,196,177,175,166,168,152,156) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Redness-Any (n=197,199,181,180,172,172,170,169) | 15.2 | 15.1 | 23.8 | 20.0 | 26.7 | 22.7 | 30.0 | 23.1 |
| Redness-Mild (n=197,198,180,180,172,171,167,165) | 14.7 | 14.1 | 22.2 | 19.4 | 24.4 | 21.1 | 28.1 | 21.2 |
| Redness-Mod (n=196,197,178,175,166,169,157,163) | 0.5 | 1.0 | 2.2 | 1.1 | 3.6 | 3.6 | 9.6 | 6.7 |
| Redness-Sev (n=196,196,177,175,166,168,152,156) | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 |
Systemic events (fever \[Fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased (Decr) appetite, irritability, increased (Incr) sleep, decreased sleep, hives, use of medication (Meds) to treat symptoms (Sx), and use of medication to prevent symptoms were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Dose 3 | 7vPnC Dose 3 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Fv ≥38°C, ≤39°C(n=201,204,181,189,172,176,156,169) | 22.9 | 19.6 | 32.6 | 41.8 | 20.9 | 29.0 | 31.4 | 34.3 |
| Fv >39°C, ≤40°C(n=196,196,177,176,166,168,154,156) | 1.0 | 0.5 | 1.7 | 1.1 | 3.6 | 3.0 | 4.5 | 2.6 |
| Fv >40°C (n=196,197,177,175,166,168,152,156) | 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 |
| Decr appetite (n=204,207,189,191,178,178,163,178) | 31.4 | 35.7 | 46.6 | 44.0 | 37.1 | 36.0 | 31.9 | 41.0 |
| Irritability (n=202,211,192,190,179,188,171,179) | 46.5 | 49.8 | 57.3 | 60.0 | 43.0 | 39.4 | 41.5 | 53.6 |
| Incr sleep (n=204,206,189,187,175,174,162,165) | 38.7 | 39.3 | 39.2 | 36.4 | 21.1 | 27.0 | 16.7 | 24.8 |
| Decr sleep (n=196,204,183,187,175,178,162,166) | 19.4 | 27.5 | 27.3 | 27.8 | 22.9 | 25.3 | 19.8 | 18.7 |
| Meds-treat sx (n=205,209,193,197,175,189,165,177) | 41.0 | 44.5 | 54.4 | 57.9 | 39.4 | 42.9 | 50.3 | 46.9 |
| Meds-prevent sx(n=201,210,194,196,177,185,168,177) | 41.3 | 45.7 | 47.9 | 49.5 | 44.6 | 40.5 | 43.5 | 41.8 |
| titer | 13vPnC After Infant Series Dose 2 | 7vPnC After Infant Series Dose 2 | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Geometric Mean Titers (GMT) for Meningococcal C Antibodies in as Measured by Serum Bactericidal Assay (SBA) 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series and the Toddler Dose | 654.55 (557.75 to 768.16) | 757.04 (648.45 to 883.81) | 2573.06 (2176.29 to 3042.16) | 2098.12 (1779.65 to 2473.58) |
Predefined antibody levels for Diphtheria (0.01 or 0.1 International units \[IU\]/mL) and Tetanus (0.01 or 0.1 \[IU\]/mL).
| percentage of participants | 13vPnC After Infant Series Dose 3 | 7vPnC After Infant Series Dose 3 | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Diphtheria ≥0.10 IU/mL | 98.5 (95.6 to 99.7) | 99.1 (96.6 to 99.9) | 100.0 (97.8 to 100.0) | 100.0 (97.9 to 100.0) |
| Diphtheria ≥0.01 IU/mL | 100.0 (98.1 to 100.0) | 100.0 (98.3 to 100.0) | 100.0 (97.8 to 100.0) | 100.0 (97.9 to 100.0) |
| Tetanus ≥0.10 IU/mL | 96.6 (92.6 to 98.7) | 96.7 (93.0 to 98.8) | 100.0 (97.8 to 100.0) | 100.0 (97.9 to 100.0) |
| Tetanus ≥0.01 IU/mL | 100.0 (97.9 to 100.0) | 100.0 (98.0 to 100.0) | 100.0 (97.8 to 100.0) | 100.0 (97.9 to 100.0) |
| IU/mL | 13vPnC After Infant Series Dose 3 | 7vPnC After Infant Series Dose 3 | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Diphtheria | 0.79 (0.69 to 0.90) | 0.92 (0.81 to 1.04) | 3.00 (2.63 to 3.41) | 3.23 (2.88 to 3.63) |
| Tetanus | 1.10 (0.94 to 1.27) | 1.20 (1.04 to 1.39) | 3.29 (2.83 to 3.83) | 3.28 (2.83 to 3.79) |
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC After Infant Series Dose 2 | 13vPnC After Infant Series Dose 3 | 13vPnC After Toddler Dose |
|---|---|---|---|
| Common Serotypes - Serotype 4 | 92.5 (87.9 to 95.7) | 98.5 (95.7 to 99.7) | 100.0 (97.7 to 100.0) |
| Common Serotypes - Serotype 6B | 27.9 (21.8 to 34.7) | 94.9 (90.9 to 97.5) | 100.0 (97.7 to 100.0) |
| Common Serotypes - Serotype 9V | 89.9 (84.8 to 93.7) | 97.0 (93.5 to 98.9) | 99.3 (96.3 to 100.0) |
| Common Serotypes - Serotype 14 | 91.0 (86.1 to 94.6) | 97.0 (93.6 to 98.9) | 99.4 (96.6 to 100.0) |
| Common Serotypes - Serotype 18C | 88.9 (83.7 to 92.9) | 99.0 (96.4 to 99.9) | 98.8 (95.6 to 99.8) |
| Common Serotypes - Serotype 19F | 100.0 (98.2 to 100.0) | 99.0 (96.4 to 99.9) | 98.7 (95.5 to 99.8) |
| Common Serotypes - Serotype 23F | 55.8 (48.6 to 62.8) | 93.0 (88.5 to 96.1) | 98.1 (94.7 to 99.6) |
| Additional Serotypes - Serotype 1 | 96.0 (92.2 to 98.2) | 98.5 (95.7 to 99.7) | 98.8 (95.6 to 99.8) |
| Additional Serotypes - Serotype 3 | 73.8 (67.1 to 79.9) | 86.2 (80.5 to 90.7) | 93.6 (88.6 to 96.9) |
| Additional Serotypes - Serotype 5 | 86.4 (80.8 to 90.8) | 96.0 (92.2 to 98.2) | 100.0 (97.6 to 100.0) |
| Additional Serotypes - Serotype 6A | 80.8 (74.6 to 86.0) | 99.0 (96.4 to 99.9) | 99.4 (96.5 to 100.0) |
| Additional Serotypes - Serotype 7F | 94.5 (90.3 to 97.2) | 100.0 (98.2 to 100.0) | 99.4 (96.5 to 100.0) |
| Additional Serotypes - Serotype 19A | 92.9 (88.4 to 96.1) | 99.5 (97.2 to 100.0) | 100.0 (97.5 to 100.0) |
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMCs (13vPnC) were calculated for each pneumococcal serotype and timepoint, and 2-sided, 95% CI were constructed.
| μg/mL | 13vPnC After Infant Series Dose 2 | 13vPnC After Infant Series Dose 3 | 13vPnC After Toddler Dose |
|---|---|---|---|
| Common Serotypes - Serotype 4 | 1.55 (1.35 to 1.78) | 2.32 (2.08 to 2.60) | 3.88 (3.42 to 4.40) |
| Common Serotypes - Serotype 6B | 0.21 (0.18 to 0.25) | 2.59 (2.20 to 3.05) | 12.25 (10.78 to 13.92) |
| Common Serotypes - Serotype 9V | 1.15 (1.01 to 1.32) | 1.51 (1.35 to 1.68) | 2.67 (2.34 to 3.05) |
| Common Serotypes - Serotype 14 | 1.94 (1.64 to 2.29) | 4.51 (3.89 to 5.22) | 9.82 (8.54 to 11.30) |
| Common Serotypes - Serotype 18C | 1.30 (1.11 to 1.51) | 1.86 (1.68 to 2.07) | 2.29 (2.01 to 2.61) |
| Common Serotypes - Serotype 19F | 2.98 (2.60 to 3.41) | 2.46 (2.21 to 2.74) | 6.11 (5.21 to 7.16) |
| Common Serotypes - Serotype 23F | 0.40 (0.34 to 0.48) | 1.67 (1.44 to 1.94) | 3.96 (3.43 to 4.59) |
| Additional Serotypes - Serotype 1 | 1.87 (1.61 to 2.16) | 2.95 (2.61 to 3.33) | 4.60 (3.94 to 5.37) |
| Additional Serotypes - Serotype 3 | 0.54 (0.48 to 0.61) | 0.85 (0.76 to 0.95) | 1.04 (0.91 to 1.19) |
| Additional Serotypes - Serotype 5 | 0.88 (0.77 to 1.00) | 1.83 (1.62 to 2.06) | 3.69 (3.26 to 4.18) |
| Additional Serotypes - Serotype 6A | 0.81 (0.70 to 0.95) | 3.08 (2.76 to 3.44) | 7.71 (6.75 to 8.80) |
| Additional Serotypes - Serotype 7F | 1.51 (1.33 to 1.71) | 3.41 (3.11 to 3.74) | 5.66 (4.90 to 6.53) |
| Additional Serotypes - Serotype 19A | 1.52 (1.31 to 1.76) | 2.50 (2.27 to 2.75) | 10.21 (8.92 to 11.68) |
Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥ 1:8 along with the corresponding 95% confidence interval (CI) are presented.
| percentage of participants | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|
| Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose | 100.0 (97.8 to 100.0) | 99.4 (96.80 to 100.0) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 6/218 (2.8%) | 204/218 (93.6%) |
| 7vPnC Infant Series | — | 8/226 (3.5%) | 211/225 (93.8%) |
| 13vPnC Post-Infant Series | — | 9/218 (4.1%) | 6/218 (2.8%) |
| 7vPnC Post-Infant Series | — | 6/226 (2.7%) | 13/225 (5.8%) |
| 13vPnC Toddler Series | — | 1/218 (0.5%) | 171/209 (81.8%) |
| 7vPnC Toddler Series | — | 0/226 (0%) | 179/218 (82.1%) |
| 13vPnC 6-Month Follow-up | — | 4/218 (1.8%) | 4/218 (1.8%) |
| 7vPnC 6-Month Follow-up | — | 9/226 (4%) | 2/224 (0.9%) |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| BronchiolitisInfections and infestations | 1/218 | 2/226 | 2/218 | 0/226 | 0/218 | 0/226 | 0/218 | 0/226 |
| PneumoniaInfections and infestations | 1/218 | 0/226 | 1/218 | 1/226 | 0/218 | 0/226 | 2/218 | 0/226 |
| GastroenteritisInfections and infestations | 1/218 | 1/226 | 0/218 | 1/226 | 0/218 | 0/226 | 0/218 | 2/226 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/218 | 0/226 | 1/218 | 0/226 | 0/218 | 0/226 | 0/218 | 0/226 |
| BronchitisInfections and infestations | 0/218 | 0/226 | 1/218 | 0/226 | 0/218 | 0/226 | 0/218 | 0/226 |
| BronchospamsRespiratory, thoracic and mediastinal disorders | 0/218 | 0/226 | 0/218 | 0/226 | 0/218 | 0/226 | 1/218 | 0/226 |
| ConvulsionNervous system disorders | 0/218 | 0/226 | 1/218 | 0/226 | 1/218 | 0/226 | 0/218 | 0/226 |
| DiarrhoeaGastrointestinal disorders | 0/218 | 0/226 | 1/218 | 0/226 | 0/218 | 0/226 | 0/218 | 1/226 |
| Enterocolitis viralInfections and infestations | 0/218 | 0/226 | 1/218 | 0/226 | 0/218 | 0/226 | 0/218 | 0/226 |
| Escherichia urinary tract infectionInfections and infestations | 1/218 | 0/226 | 0/218 | 0/226 | 0/218 | 0/226 | 0/218 | 0/226 |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| IrritabilityGeneral disorders | 202/218 | 211/225 | — | — | 171/209 | 179/218 | — | — |
| Decreased appetiteGeneral disorders | 204/218 | 207/225 | — | — | 163/209 | 178/218 | — | — |
| Increased sleepGeneral disorders | 204/218 | 206/225 | — | — | 162/209 | 165/218 | — | — |
| Fever ≥38°C but ≤39°CGeneral disorders | 201/218 | 204/225 | — | — | 156/209 | 169/218 | — | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 199/218 | 205/225 | — | — | 164/209 | 172/218 | — | — |
| Tenderness (significant)Skin and subcutaneous tissue disorders | 199/218 | 200/225 | — | — | 154/209 | 160/218 | — | — |
| Decreased sleepGeneral disorders | 196/218 | 204/225 | — | — | 162/209 | 166/218 | — | — |
| Erythema (any)Skin and subcutaneous tissue disorders | 197/218 | 199/225 | — | — | 170/209 | 169/218 | — | — |
| Erythema (mild)Skin and subcutaneous tissue disorders | 197/218 | 198/225 | — | — | 167/209 | 165/218 | — | — |
| Induration (any)Skin and subcutaneous tissue disorders | 196/218 | 200/225 | — | — | 169/209 | 168/218 | — | — |
| Age Continuous(months) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 2.1 ± 0.4 | 2.0 ± 0.4 | 2.1 ± 0.4 |
| Sex: Female, Male(Participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 104 | 116 | 220 |
| Male | 115 | 109 | 224 |
The record gives a start of Jul 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →